{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:30:21Z","timestamp":1793406621630,"version":"4.5.0"},"reference-count":28,"publisher":"Georg Thieme Verlag KG","issue":"11","funder":[{"name":"Grant for Precursory Research for Embryonic Science and Technology"},{"name":"Grant-in-Aid for Scientific Research","award":["#22K08209"],"award-info":[{"award-number":["#22K08209"]}]},{"name":"Grant-in-Aid for Scientific Research","award":["#25K02647"],"award-info":[{"award-number":["#25K02647"]}]},{"name":"Japan Agency for Medical Research and Development","award":["# JP24he2622006"],"award-info":[{"award-number":["# JP24he2622006"]}],"id":[{"id":"https:\/\/ror.org\/004rtk039","id-type":"ROR","asserted-by":"crossref"}]},{"name":"TAUNS Laboratories, Inc."},{"name":"Thrombo Translational Research Labo Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Initial thrombin (FIIa) generation is a critical trigger for the amplification and propagation phases of coagulation, driven by two distinct pathways: the tissue factor (TF)-driven and the FVIIIa\/FIXa-dependent pathways. However, the clinical utility of measuring initial thrombin generation (ITG) as a marker of thrombogenicity or as a tool to monitor the efficacy of oral anti-FXa therapy remains uncertain.<\/jats:p>\n                  <jats:p>ITG driven by TF and the FVIIIa\/FIXa complex was first measured in plasma samples from healthy adults (n\u2009=\u200940). This was followed by an analysis of ITG profiles in 771 consecutive patients with cardiovascular diseases to evaluate the effects of anticoagulant therapy and clinical characteristics.<\/jats:p>\n                  <jats:p>Of the 771 patients studied, 169 were receiving direct oral anticoagulants (DOACs). DOAC treatment significantly suppressed thrombin generation via both TF-driven and FVIIIa\/FIXa-dependent pathways. Receiver operating characteristic (ROC) analysis confirmed the strong discriminatory power of both pathways for detecting DOAC use (FVIIIa\/FIXa: AUC 0.863, 95% CI: 0.826\u20130.900; TF: AUC 0.887, 95% CI: 0.856\u20130.917; both p values\u2009&lt;\u20090.0001). Among patients not on anticoagulants, logistic regression revealed that dialysis was associated with reduced thrombin generation through both pathways. Furthermore, chronic kidney disease and active cancer were specifically associated with diminished TF-driven thrombin generation.<\/jats:p>\n                  <jats:p>The ITG potentials driven by TF- and FVIIIa\/FIXa-dependent pathways represent promising biomarkers for evaluating anticoagulant efficacy. Moreover, the distinct influence of pathological conditions on each pathway underscores the need to account for specific disease contexts when assessing coagulation potential.<\/jats:p>","DOI":"10.1055\/a-2751-8379","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:01:11Z","timestamp":1763769671000},"page":"1166-1178","source":"Crossref","is-referenced-by-count":2,"title":["Profiling Initial Thrombin Generation in Cardiovascular Disease Using a High Sensitivity Coagulation Assay"],"prefix":"10.1055","volume":"126","author":[{"given":"Akira","family":"Fujiyama","sequence":"additional","affiliation":[{"name":"Developmental Cardiology Laboratory, International Research Center for Medical Science (IRCMS), Kumamoto University, Kumamoto, Japan"},{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Arima","sequence":"additional","affiliation":[{"name":"Developmental Cardiology Laboratory, International Research Center for Medical Science (IRCMS), Kumamoto University, Kumamoto, Japan"},{"name":"Center for Metabolic Regulation of Healthy Aging, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan"},{"name":"Department of Anatomy, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Inoue","sequence":"additional","affiliation":[{"name":"Thrombo Translational Research Lab Inc., Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Kuyama","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Hirakawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan"},{"name":"Department of Medical Information Science, Graduate School of Medical Sciences, Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Hanatani","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Matsuzawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichiro","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Izumiya","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Komatsu","sequence":"additional","affiliation":[{"name":"Tauns Laboratories Inc., Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6614-7411","authenticated-orcid":false,"given":"Yuichi","family":"Kamikubo","sequence":"additional","affiliation":[{"name":"Thrombo Translational Research Lab Inc., Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Tsujita","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan"},{"name":"Center for Metabolic Regulation of Healthy Aging, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"issue":"23","key":"ref1","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1093\/eurheartj\/ehab128","article-title":"Antithrombotic therapy in diabetes: which, when, and for how long?","volume":"42","author":"R A Ajjan","year":"2021","journal-title":"Eur Heart J"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.thromres.2022.08.015","article-title":"Challenging clinical scenarios for therapeutic anticoagulation: a practical approach","volume":"218","author":"K L Martens","year":"2022","journal-title":"Thromb Res"},{"issue":"02","key":"ref3","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1253\/circj.CJ-24-0614","article-title":"10-year trends of antithrombotic therapy status and clinical outcomes in patients with atrial fibrillation and renal dysfunction\u2014the Fushimi AF Registry","volume":"89","author":"N Masunaga","year":"2025","journal-title":"Circ J"},{"issue":"02","key":"ref4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s11239-021-02458-8","article-title":"Roles of factor Xa beyond coagulation","volume":"52","author":"W Ruf","year":"2021","journal-title":"J Thromb Thrombolysis"},{"issue":"02","key":"ref5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1253\/circj.CJ-24-0418","article-title":"Impact of underdosing of direct oral anticoagulants on clinical outcomes in patients with atrial fibrillation undergoing percutaneous coronary intervention","volume":"89","author":"H Kitahara","year":"2025","journal-title":"Circ J"},{"issue":"12","key":"ref6","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","article-title":"Antithrombotic therapy for atrial fibrillation with stable coronary disease","volume":"381","author":"S Yasuda","year":"2019","journal-title":"N Engl J Med"},{"issue":"05","key":"ref7","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1056\/NEJMra1607714","article-title":"Management of antithrombotic therapy after acute coronary syndromes","volume":"384","author":"F Rodriguez","year":"2021","journal-title":"N Engl J Med"},{"issue":"03","key":"ref8","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jtha.2022.11.029","article-title":"DOAC-associated bleeding, hemostatic strategies, and thrombin generation assays\u2014a review of the literature","volume":"21","author":"J R Shaw","year":"2023","journal-title":"J Thromb Haemost"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"100582","DOI":"10.1016\/j.blre.2019.05.006","article-title":"The central role of thrombin in bleeding disorders","volume":"38","author":"C Negrier","year":"2019","journal-title":"Blood Rev"},{"issue":"01","key":"ref10","doi-asserted-by":"crossref","first-page":"100018","DOI":"10.1016\/j.rpth.2022.100018","article-title":"Thrombin generation and implications for hemophilia therapies: a narrative review","volume":"7","author":"R F Sidonio Jr","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"10","key":"ref11","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1161\/ATVBAHA.117.306995","article-title":"Impact of non-vitamin K antagonist oral anticoagulants from a basic science perspective","volume":"37","author":"M Hoffman","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"14","key":"ref12","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1182\/blood-2017-02-767079","article-title":"Selective factor VIII activation by the tissue factor-factor VIIa-factor Xa complex","volume":"130","author":"Y Kamikubo","year":"2017","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1055\/a-2552-2050","article-title":"Tissue factor pathway-driven initial thrombin generation is associated with hypercoagulability in obesity","author":"Y Kamikubo","year":"2025","journal-title":"Thromb Haemost"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"e03","DOI":"10.15420\/ecr.2024.17","article-title":"Direct oral anticoagulant use in older adults with atrial fibrillation: challenges and solutions","volume":"20","author":"M Bhandari","year":"2025","journal-title":"Eur Cardiol"},{"issue":"21","key":"ref15","doi-asserted-by":"crossref","first-page":"e029865","DOI":"10.1161\/JAHA.122.029865","article-title":"Benefits and harms of standard versus reduced-dose direct oral anticoagulant therapy for older adults with multiple morbidities and atrial fibrillation","volume":"12","author":"K N Hayes","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"03","key":"ref16","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s40262-023-01222-w","article-title":"Insights into the pharmacokinetics and pharmacodynamics of direct oral anticoagulants in older adults with atrial fibrillation: a structured narrative review","volume":"62","author":"A E Edwina","year":"2023","journal-title":"Clin Pharmacokinet"},{"issue":"07","key":"ref17","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrcardio.2012.19","article-title":"Oral direct factor Xa inhibitors for stroke prevention in atrial fibrillation","volume":"9","author":"K P Cabral","year":"2012","journal-title":"Nat Rev Cardiol"},{"issue":"10","key":"ref18","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1111\/jth.14254","article-title":"Mortality due to bleeding, myocardial infarction and stroke in dialysis patients","volume":"16","author":"G Ocak","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref19","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.thromres.2013.09.002","article-title":"Plasma haemostatic potential of haemodialysis patients assessed by thrombin generation assay: hypercoagulability in patients with vascular access thrombosis","volume":"132","author":"J C Jeong","year":"2013","journal-title":"Thromb Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.thromres.2023.04.016","article-title":"Global coagulation assays in patients with chronic kidney disease and their role in predicting thrombotic risk","volume":"226","author":"H Y Lim","year":"2023","journal-title":"Thromb Res"},{"issue":"01","key":"ref21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12959-025-00719-7","article-title":"Cancer-associated venous thromboembolism: a comprehensive review","volume":"23","author":"T Wan","year":"2025","journal-title":"Thromb J"},{"issue":"02","key":"ref22","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1253\/circj.CJ-20-1247","article-title":"Mortality, recurrent thromboembolism and major bleeding in cancer-associated and non-cancer pulmonary embolism patients treated with direct oral anticoagulants","volume":"88","author":"Y Nakano","year":"2024","journal-title":"Circ J"},{"issue":"12","key":"ref23","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41416-022-01968-3","article-title":"Tissue factor in cancer-associated thromboembolism: possible mechanisms and clinical applications","volume":"127","author":"S Koizume","year":"2022","journal-title":"Br J Cancer"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"109073","DOI":"10.1016\/j.thromres.2024.109073","article-title":"Elevated TFPI is a prognostic factor in hepatocellular carcinoma: putative role of miR-7-5p and miR-1236-3p","volume":"241","author":"M Sletten","year":"2024","journal-title":"Thromb Res"},{"issue":"05","key":"ref25","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.thromres.2013.09.016","article-title":"Tumour expresion of tissue factor and tissue factor pathway inhibitor in ovarian cancer\u2014relationship with venous thrombosis risk","volume":"132","author":"F Abu Saadeh","year":"2013","journal-title":"Thromb Res"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1055\/s-0042-1760490","article-title":"Tissue factor pathway inhibitor is associated with risk of venous thromboembolism and all-cause mortality in patients with cancer","volume":"43","author":"C Englisch","year":"2023","journal-title":"Hamostaseologie"},{"issue":"04","key":"ref27","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1046\/j.1365-2141.1998.00875.x","article-title":"Elevated TFPI in malignant disease: relation to cancer type and hypercoagulation","volume":"102","author":"N Iversen","year":"1998","journal-title":"Br J Haematol"},{"issue":"04","key":"ref28","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0049-3848(98)00126-1","article-title":"Influence of low- and high-dose aspirin treatment on thrombin generation in whole blood","volume":"92","author":"N H Wall\u00e9n","year":"1998","journal-title":"Thromb Res"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2751-8379.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:34:45Z","timestamp":1793403285000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2751-8379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":28,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,10,30]]},"published-print":{"date-parts":[[2026,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2751-8379","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,21]]},"published":{"date-parts":[[2025,11,21]]}}}